English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduCedars-Sinai Cancer physician-scientists with expertise in liver, skin, lung, breast, colorectal, pancreatic, brain, prostate and endometrial cancers will be attending the American Society of Clinical Oncology annual meeting June 2-6 in Chicago and are available for in-person or virtual interviews to discuss the latest news and research.
Tag: Androgen Deprivation Therapy
Hormone therapy could lower risk of immunotherapy-associated myocarditis in women
A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center and the University of California San Francisco (UCSF) has discovered the underlying cause of gender differences in immunotherapy-associated myocarditis after immune checkpoint inhibitor (ICI) treatment. Their findings point to possible treatment strategies for this side effect, which disproportionately affects female patients.
Cedars-Sinai Radiation Oncologists Featured at ASTRO 2022
Physician scientists from the Department of Radiation Oncology at Cedars-Sinai Cancer will present research and discuss advances in clinical care at the American Society for Radiation Oncology (ASTRO) annual meeting Oct. 23-26 in San Antonio.
Moffitt Researchers Contribute to Discovery of Mechanism Leading to Drug Resistance in Prostate Cancer
In a new article published in Science Translational Medicine, Moffitt Cancer Center researchers reveal a mechanism by which prostate cancer cells become resistant through molecular modification of the androgen receptor protein and identify a potential treatment approach that could overcome this resistance.
Hormones Contribute to Sex Disparities in Bladder Cancer, Study Shows
Male sex hormones interfere with the body’s ability to fight bladder cancer, likely explaining why males experience higher cancer rates and more deadly disease, according to a new study co-led by a Cedars-Sinai Cancer investigator.
New Combined Therapy Helps Extend Lives of Men With Prostate Cancer
Practice-changing research from Cedars-Sinai Cancer shows that a combination of androgen deprivation therapy—a commonly used hormone injection—plus pelvic lymph node radiation, kept nearly 90% of clinical trial patients’ prostate cancer at bay for five years. The findings were published in the peer-reviewed journal The Lancet.
JNCCN: New Research Finds Low Bone Health Testing Rates after Prostate Cancer Treatment
New research in the October 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds the rate of bone mineral density (BMD) testing in people with prostate cancer undergoing androgen deprivation therapy (ADT) has improved in recent years, but remains low.
Researchers Validate Link Between Genetic Variant and Poor Outcomes in Men with Advanced Prostate Cancer
In a new Cleveland Clinic-led study published in JAMA Oncology, researchers show that a testosterone-related genetic variant – HSD3B1(1245C) – is associated with more aggressive disease and shorter survival in men with metastatic prostate cancer.